Two cases of refractory thrombocytopenia in systemic lupus erythematosus that responded to intravenous low-dose cyclophosphamide

Journal of Korean Medical Science

Volumn 28, Issue 3, 2013, Pages 472-475

  Park, Hee Jin ^a   Kang, Mi il ^a   Kang, Yoon ^a   Chung, Soo jin ^a   Lee, Sang Won ^a   Park, Yong Beom ^a   Lee, Soo Kon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Cyclophosphamide; Systemic lupus erythematosus; Thrombocytopenia

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; BONE MARROW; CASE REPORT; DRUG COMBINATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

CYCLOPHOSPHAMIDE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

AZATHIOPRINE; BONE MARROW; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MYCOPHENOLIC ACID; PLATELET COUNT; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 84875760687     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.3.472     Document Type: Article

References (13)

1. Hepburn AL, Narat S, Mason JC. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology (Oxford) 2010; 49: 2243-54.
2. Boumpas DT, Barez S, Klippel JH, Balow JE. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1990; 112: 674-7.
3. Arnal C, Piette JC, Léone J, Taillan B, Hachulla E, Roudot-Thoraval F, Papo T, Schaeffer A, Bierling P, Godeau B. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002; 29: 75-83.
4. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 1995; 85: 351-8.
5. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-4.
6. Sultan SM, Begum S, Isenberg DA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology (Oxford) 2003; 42: 230-4.
7. Roach BA, Hutchinson GJ. Treatment of refractory, systemic lupus erythematosus- associated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide. Arthritis Rheum 1993; 36: 682-4.
8. Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 2003; 12: 630-2.
9. Hall S, McCormick JL Jr, Greipp PR, Michet CJ Jr, McKenna CH. Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. Ann Intern Med 1985; 102: 325-8.
10. You YN, Tefferi A, Nagorney DM. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann Surg 2004; 240: 286-92.
11. Alarcon-Segovia D. Splenectomy has a limited role in the management of lupus with thrombocytopenia. J Rheumatol 2002; 29: 1-2.
12. Gorman C, Bhatia A, Rahman A. This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis. Rheumatology (Oxford) 2005; 44: 398-401.
13. Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2005; 14: s33-8.